Douglas Miller, M.D.,medical director of Radiation Oncology at Jersey Shore University Medical Center recently spearheaded a multi-institutional clinical trial that investigated the effectiveness of a new medication administered to patients within an hour before radiation treatment to reduce the severity and duration of mucositis in patients receiving treatment for head and neck cancers.
The results from the clinical trial, spearheaded at Jersey Shore University Medical Center was published in the Journal of Clinical Oncology’s October 2019 issue.
The positive findings from this trial have fostered the opening of three new ongoing clinical trials at Jersey Shore to determine whether the same medication can prevent radiation-induced side effects for patients with head and neck or lung cancers.
Dr. Miller is Hackensack Meridian Health’s Principal Investigator of cooperative trials for Radiation Oncology and sub-investigator on protocols within the network and its partners. At Jersey Shore, part of Hackensack Meridian Health Cancer Care, the Radiation Oncology team employs a collaborative care model, an approach to treatment that helps patients deal with the range of emotions and increased stress that often comes along with a cancer diagnosis. The program includes an expert clinical team, advanced treatment options and comfortable environment.
Click here to view the Journal of Clinical Oncology report.